Company Monitoring Page for Gilead-Sciences

latest headlines for company on cafepharma

This Army Vet Is Fighting Hep C With Big Pharma’s Help
Bloomberg
Thu, 12/29/16 - 10:18 am
Tags:
hepatitis C, AbbVie, Merck, Gilead Sciences
The Most Likely Incyte Acquisition Deal for 2017?
Motley Fool
Sat, 12/24/16 - 12:11 pm
Tags:
M&A, Incyte, Gilead Sciences, Lilly, Novartis, Agenus
Valeant Is The Answer To Gilead's Problems
Seeking Alpha
Fri, 12/23/16 - 09:53 am
Tags:
Valeant Pharmaceuticals, Gilead Sciences
Will 2017 Be Gilead Sciences Inc.'s Worst Year Yet?
Motley Fool
Thu, 12/22/16 - 10:15 am
Tags:
Gilead Sciences
Could Gilead Sciences' Game-Changing HIV Pill Solve Its Growth Problem?
Motley Fool
Tue, 12/20/16 - 12:11 pm
Tags:
Gilead Sciences, HIV, Truvada
The Most Expensive Drugs of 2016
Motley Fool
Mon, 12/19/16 - 11:32 am
Tags:
drug pricing, Gilead Sciences, Harvoni, Sovaldi, H.P. Acthar, Mallinckrodt, Shire, Cinryze, Daklinza, Bristol-Myers Squibb
Gilead’s Patent Loss to Merck Started With a Broken Friendship
Bloomberg
Mon, 12/19/16 - 10:55 am
Tags:
Gilead Sciences, Merck, patents, hepatitis C, Sovaldi, Harvoni
Could These 2 Small Biotechs Beat Allergan and Gilead Sciences?
Motley Fool
Sat, 12/17/16 - 12:23 pm
Tags:
biotech, Allergan, Gilead Sciences, Genfit, Intercept Pharmaceuticals, NASH
Merck Wins Record $2.5 Billion Patent Verdict Against Gilead
Bloomberg
Fri, 12/16/16 - 09:51 am
Tags:
Merck, patents, Gilead Sciences, hepatitis C, Harvoni, Sovaldi
Gilead Sciences Inc.'s Best Moves in 2016
Motley Fool
Thu, 12/15/16 - 12:00 pm
Tags:
Gilead Sciences, NASH, hepatitis C, filgotinib, Galapagos
The 3 Most Profit-Friendly Biotech Stocks
Motley Fool
Tue, 12/13/16 - 10:23 am
Tags:
biotech, biotech stocks, United Therapeutics, Gilead Sciences, Biogen
Gilead's HCV NDA Means Nothing
Seeking Alpha
Sun, 12/11/16 - 11:55 am
Tags:
Gilead Sciences, hepatitis C, SOF/VEL/VOX, Epclusa, AbbVie
Gilead offers rare apology to payers over the hep C drug sticker shock
Endpoints
Thu, 12/8/16 - 10:06 am
Tags:
Gilead Sciences, drug pricing, Pharma CEOs, Sovaldi, John Milligan
Gilead Sciences Inc.'s Worst Moves in 2016
Motley Fool
Tue, 12/6/16 - 10:44 pm
Tags:
Gilead Sciences, dividends, hepatitis C, M&A
Switching course, Gilead markets HIV drug for prevention
Yahoo/Reuters
Thu, 12/1/16 - 10:28 am
Tags:
Truvada, Gilead Sciences, HIV
5 Things Gilead Sciences' CEO Just Said That You Need to Know
Motley Fool
Wed, 11/30/16 - 09:49 pm
Tags:
Gilead Sciences, John Milligan, Pharma CEOs
Gilead's Meyers on making deals and finding unmet patient needs
Medical Marketing and Media
Wed, 11/30/16 - 10:00 am
Tags:
Gilead Sciences, patients
Gilead Takes Lead on Crohn's over AbbVie
Investopedia
Mon, 11/28/16 - 11:33 pm
Tags:
Gilead Sciences, AbbVie, Crohn's Disease, Galapagos, filgotinib, ABT-494
Gilead Sciences' HCV Fall Was Partially Offset by HIV Business
Market Realist
Mon, 11/28/16 - 11:26 pm
Tags:
Gilead Sciences, hepatitis C, HIV
Gilead's Looming Challenge: A Plan B For HBV
Seeking Alpha
Tue, 11/22/16 - 11:35 am
Tags:
Gilead Sciences, hepatitis B, GS-9620

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.